Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.03 EUR
Change Today +0.004 / 0.08%
Volume 0.0
As of 3:54 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

pacific biosciences of calif (P09) Snapshot

Open
€5.08
Previous Close
€5.03
Day High
€5.13
Day Low
€5.03
52 Week High
01/28/15 - €7.50
52 Week Low
08/4/14 - €3.24
Market Cap
375.1M
Average Volume 10 Days
300.0
EPS TTM
--
Shares Outstanding
74.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PACIFIC BIOSCIENCES OF CALIF (P09)

pacific biosciences of calif (P09) Related Bloomberg News

View More Bloomberg News

pacific biosciences of calif (P09) Related Businessweek News

View More BusinessWeek News

pacific biosciences of calif (P09) Details

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company provides single molecule real-time (SMRT) technology platform, which enables single molecule real-time detection of biological processes. It offers PacBio RS II high resolution genetic analyzer, an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company provides consumable products, which include sealed and packaged SMRT Cells, as well as various reagent kits, such as template preparation kits, binding kits, and sequencing kits to run the PacBio RS II. Its customers include research institutions, commercial laboratories, genome centers, clinical, government and academic institutions, genomics service providers, pharmaceutical companies, and agricultural companies. The company markets its products through a direct sales force in North America and Europe as well as primarily through distributors in Asia. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

344 Employees
Last Reported Date: 03/12/15
Founded in 2000

pacific biosciences of calif (P09) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $1.0
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $1.0
Senior Vice President of Market Development
Total Annual Compensation: $399.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: $399.0K
Compensation as of Fiscal Year 2014.

pacific biosciences of calif (P09) Key Developments

Pacific Biosciences of California, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Pacific Biosciences of California, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $17,645,000 compared to $11,642,000 a year ago. Operating loss was $19,328,000 compared to $18,245,000 a year ago. Net loss was $20,173,000 or $0.27 per basic and diluted share compared to $18,886,000 or $0.28 per basic and diluted share a year ago.

Pacific Biosciences of California, Inc. and RainDance Technologies, Inc. Partner to Co-Develop and Commercialize Novel Solution For de novo Whole Genome Assembly

Pacific Biosciences of California, Inc. and RainDance Technologies, Inc. announced their entry into a co-development and co-marketing agreement to commercialize novel solutions for de novo whole genome assembly. These solutions will combine the power of RainDance's proprietary digital droplet technology and single-molecule barcoding capabilities with Pacific Biosciences' proprietary long-range DNA amplification technology to provide sample preparation upstream of PacBio's long-read sequencing system. This combination could provide a method to generate millions of long, single-molecule barcoded DNA fragments, averaging 10-30 kilobases that originated from much longer (100 kilobase) fragments. Combining this fragmentation and labeling scheme with a sequence context-unbiased amplification method for long DNA fragments, PacBio sequencing could provide de novo, haplotype-phased assembly of complex genomes. This would be possible even in genomic regions containing complex repeats or PCR-challenged sequences that limit performance of synthetic long-read approaches based upon short-read sequencing technologies. Furthermore, this approach will be designed to work with low DNA input as little as 1 ng to address scarce or difficult-to-procure samples.

Pacific Biosciences Introduces New Solutions for Comprehensive and Efficient Targeted Sequencing and Multiplexing of Samples

Pacific Biosciences of California, Inc. announced the introduction of several new solutions for targeted sequencing applications. The company has introduced a new workflow that combines Roche NimbleGen's SeqCap EZ enrichment technology with large DNA fragments (up to 6 kb) and PacBio's Single Molecule, Real-Time (SMRT®) Sequencing to provide a more comprehensive view of variants, transgene integration sites, and haplotype information over multi-kilobase contiguous regions. The long fragments capture haplotype information that provide a more inclusive view of the targeted region of interest, allowing a comprehensive look at variants in exons, introns and intergenic regions, as well as generation of accurate haplotypes. PacBio also announced the launch of two multiplexing workflows and associated products for barcoding samples prior to running on SMRT Cells. The new barcoding kits allow customers to pool many samples and thus reduce the cost per sample and the total time for sample preparation. By employing the barcoding strategies, researchers can efficiently focus on even more defined genomic regions. And by barcoding samples, researchers have the flexibility to multiplex samples or targets within a sample or a combination of both.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
P09:GR €5.03 EUR +0.004

P09 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.48 USD +0.05
Fluidigm Corp $23.69 USD +0.05
NanoString Technologies Inc $14.62 USD +0.58
Sequenom Inc $3.36 USD +0.01
WaferGen Bio-systems Inc $3.99 USD +0.14
View Industry Companies
 

Industry Analysis

P09

Industry Average

Valuation P09 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book 10.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIFIC BIOSCIENCES OF CALIF, please visit www.pacificbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.